{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'In cases where the participant is deemed \"lost to follow up\\', the investigator or', 'designee must make every effort to regain contact with the participant (where', \"possible, 3 telephone calls and if necessary a certified letter to the participant's\", 'last known mailing address or local equivalent methods). These contact', \"attempts should be documented in the participant's medical record.\", 'Should the participant continue to be unreachable, only then will he/she be', 'considered to have withdrawn from the study with a primary reason of \"Lost to', 'Follow-up.\"', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', 'A signed, written informed consent form must be obtained from the participant prior to', 'any study-specific procedures or assessments being performed. The timing of each', 'assessment is listed in the Schedule of Activities (Table 1).', 'A list of clinical laboratory tests is displayed in Table 14.', 'Whenever vital signs, 12-lead electrocardiograms (ECGs) and blood draws are scheduled', 'for the same nominal time, the assessments must occur in the following order: 12-lead', 'ECG, vital signs, blood draws. The timing of the assessments must allow the blood draw', 'to occur at the exact nominal time. Detailed procedures for obtaining each assessment', 'are provided in the SRM.', 'Study procedures and their timing are summarized in the SOA (Table 1 - Table', '3).', 'Protocol waivers or exemptions are not allowed.', 'Demographic and baseline assessments will include year of birth, sex, race, and', 'ethnicity.', 'Medical/medication/family history will be assessed as related to the', 'inclusion/exclusion criteria listed in Section 6.1 and Section 6.2.', 'Immediate safety concerns must be discussed with the sponsor immediately', 'upon occurrence or awareness to determine if the participant should continue or', 'discontinue study treatment.', 'Adherence to the study design requirements, including those specified in the', 'SOA, is essential and required for study conduct.', 'All screening evaluations must be completed and reviewed to confirm that', 'potential participants meet all eligibility criteria. The investigator will maintain', 'a screening log to record details of all participants screened and to confirm', 'eligibility or record reasons for screening failure, as applicable.', \"Procedures conducted as part of the participant's routine clinical management\", '(e.g., blood count) and obtained before signing of ICF may be utilized for', 'screening or baseline purposes provided the procedure met the protocol-', 'specified criteria and was performed within the time frame defined in the SOA.', '71']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Survival follow-up can be conducted by phone call.', 'Baseline disease assessments must be completed with 21 days prior to dosing', 'start unless otherwise specified. Refer to SOA.', 'Screening assessments performed within the permitted time do not need to be', 'repeated on C1D1 unless otherwise specified.', 'Safety labs completed within 72 hours of first dose do not need to be repeated', 'on C1D1.', 'Pregnancy testing must be completed within 72 hours prior to first dose.', 'ECHO must be completed within 35 days prior to first dose.', 'Imaging must be completed within 30 days prior to first dose.', 'On-study visits have a +3-day window', 'PFS follow-up visits have a +7-day window.', 'Survival follow-up visits have a +14-day window.', '72']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 14', 'List of Clinical Laboratory Tests', 'Hematology1', 'Platelet Count', 'RBC Indices:', 'Automated WBC', 'Differential:', 'Red blood cell (RBC) Count', 'MCV', 'Neutrophils', 'White blood cell (WBC)', 'MCH', 'Lymphocytes', 'Count (absolute)', 'Reticulocyte Count', 'MCHC', 'Monocytes', 'Hemoglobin', 'Eosinophils', 'Hematocrit', 'Basophils', 'Clinical Chemistry1', 'Blood urea nitrogen (BUN)', 'Potassium', 'Aspartate aminotransferase', 'Total and direct', '(AST)', 'bilirubin', 'Creatinine', 'Chloride', 'Alanine aminotransferase', 'Uric Acid', '(ALT)', 'Glucose', 'Total bicarbonate', 'Gamma glutamyl transferase', 'Albumin', '(GGT)', 'Sodium', 'Calcium', 'Alkaline phosphatase', 'Total Protein', 'Magnesium', 'Phosphorous', 'Creatine kinase (CK)', 'LDH', 'eGFR', 'Spot urine (albumin /', 'creatinine ratio)5,', 'Urine\u00b9', 'Routine Urine Dipstick (Urinalysis required if blood or protein is detected by dipstick)', 'Specific gravity', 'pH, glucose, protein, blood and ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other Safety', 'C-reactive protein (CRP)', 'Troponin |5', 'B-type natriuretic peptide (BNP)5', 'Follicle stimulating hormone (FSH) and estradiol (as needed in women of non-child bearing potential only) (screening)', 'Pregnancy Test (urine or blood- per local practice)\u00b9', 'Hepatitis B surface antigen (HBsAg)\u00b9', 'Hepatitis B core antibody (HBcAb)1', 'Hepatitis C (Hep C antibody)1', 'Note: Hep C RNA testing is optional but may be done to determine participant eligibility if Hep C antibody positive).', 'Participants with positive Hepatitis C antibody due to prior resolved disease may be offered hepatitis C RNA testing to', 'determine eligibility.', '73']\n\n###\n\n", "completion": "END"}